TargetMol

SCH-37370

Product Code:
 
TAR-T19686
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T19686-1mg1mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19686-5mg5mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19686-1mL1 mL * 10 mM (in DMSO)£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19686-10mg10mg£295.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19686-25mg25mg£474.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19686-50mg50mg£655.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19686-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SCH-37370 is an effective and orally active dual antagonist of platelet-activating factor and histamine. Sch 37370 blocks the binding of [3H]pyrilamine to histamine-H1 receptors in rat brain membranes. Sch 37370 selectively inhibits PAF-induced aggregation of human platelets (IC50 : 0.6 mM) and also competes with PAF binding to specific sites in membrane preparations from human lungs (IC50 : 1.2 mM).
CAS:
117796-52-8
Formula:
C21H21ClN2O
Molecular Weight:
352.86
Purity:
0.9992
SMILES:
CC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12
Target:
Platelet aggregation

References

1. Kaminski JJ, Carruthers NI, Wong SC, Chan TM, Billah MM, Tozzi S, McPhail AT. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Bioorg Med Chem. 1999 Jul;7(7):1413-23. PubMed PMID: 10465415. 2. Centemeri C, Colli S, Tosarello D, Ciceri P, Nicosia S. Heterogeneous platelet-activating factor (PAF) receptors and calcium increase in platelets and macrophages. Biochem Pharmacol. 1999 Feb 1;57(3):263-71. PubMed PMID: 9890553. 3. Negro Alvarez JM, Miralles L?pez JC, Ortiz Mart?nez JL, Abell?n Alem?n A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010. 4. Balsa D, Merlos M, Giral M, Ferrando R, Garc?a-Rafanell J, Forn J. Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard method. J Pharmacol Toxicol Methods. 1996 Sep;36(1):53-62. PubMed PMID: 8872920.